Skip to content
Peptigraph home
Shop Peptides50% off*

Does retatrutide lower blood sugar?

Yes, in people with diabetes. In the monotherapy trial, HbA1c fell by 1·94% on 12 mg against 0·81% on placebo.

GLP-1 / GIP / glucagon triple agonistUpdated

Short answer

Yes, in people with diabetes. In the monotherapy trial, HbA1c fell by 1·94% on 12 mg against 0·81% on placebo.[1]

In the earlier dose-finding trial, HbA1c fell by 2·02% on the 12 mg escalation arm, against 0·01% on placebo and 1·41% on dulaglutide 1·5 mg.[2]

Low blood sugar and the larger trial

The dose-finding trial reported no severe hypoglycaemia.[2]

The monotherapy trial likewise reported no severe hypoglycaemia.[1]

A larger trial in adults with obesity and diabetes described improved glycaemic control alongside large weight loss.[3]

More questions on Retatrutide

Can retatrutide cause cancer?Can retatrutide cause high blood pressure?Can retatrutide cause joint pain?Can retatrutide cause pancreatitis?Can women take retatrutide?Can you build muscle on retatrutide?

More on Retatrutide

ResultsStudy outcomes and when they were measured.Retatrutide overview

Sources

  1. 1Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.Lancet (London, England) · 2026PMID 42250575Accessed 2 Oct 2026
  2. 2Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.Lancet (London, England) · 2023PMID 37385280Accessed 2 Oct 2026
  3. 3Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.Lancet (London, England) · 2026PMID 42810372Accessed 2 Oct 2026

Found an error? Report a correction.